Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-AML2015 study in pediatric acute myeloid leukemia
ChiCTR-IPR-15006816Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jul 2015
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of daunorubicin, cytarabine, homoharringtonine, etoposide and tretinoin in acute myeloid leukemia (AML) (4 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Bone marrow remission status, Minimal residual disease and 1 more. Started Jul 2015; status: recruiting.
02
Drugs
daunorubicincytarabinehomoharringtonineetoposidetretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IPR-15006816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006816.